insitro
@insitro.bsky.social
insitro is a machine learning-enabled drug discovery and development company. By leveraging human and cellular data, we uncover novel genetic targets and therapeutic hypotheses to increase the probability of success of new medicines. www.insitro.com
insitro founder and CEO Daphne Koller sat down with BiotechTV during #JPM26. Daphne discusses how AI is helping insitro accelerate drug discovery and translate data into meaningful therapeutic insight. www.biotechtv.com/post/insitro...
SF Healthcare Week: Insitro CEO Daphne Koller on how AI is hitting “escape velocity” for finding causal targets for disease and speeding up drug development
An early pioneer in the space, she describes the current state of AI in life sciences and the progress that Insitro is making.Daphne Kolher
www.biotechtv.com
January 16, 2026 at 7:47 PM
insitro founder and CEO Daphne Koller sat down with BiotechTV during #JPM26. Daphne discusses how AI is helping insitro accelerate drug discovery and translate data into meaningful therapeutic insight. www.biotechtv.com/post/insitro...
insitro acquired CombinAbleAI & launched TherML™, completing a unified, modality-agnostic AI platform for therapeutic design across small molecules, biologics, & oligonucleotides, optimizing potency & developability from the start. 🔗 www.insitro.com/news/combina...
🔗 www.insitro.com/news/introdu...
🔗 www.insitro.com/news/introdu...
January 12, 2026 at 5:23 PM
insitro acquired CombinAbleAI & launched TherML™, completing a unified, modality-agnostic AI platform for therapeutic design across small molecules, biologics, & oligonucleotides, optimizing potency & developability from the start. 🔗 www.insitro.com/news/combina...
🔗 www.insitro.com/news/introdu...
🔗 www.insitro.com/news/introdu...
insitro will present at #JPM26. CEO Daphne Koller will share progress across our AI-enabled discovery engine & programs advancing toward the clinic, w/ additional participation from our leadership team throughout the week.
www.insitro.com/news/insitro...
www.insitro.com/news/insitro...
January 6, 2026 at 9:31 PM
insitro will present at #JPM26. CEO Daphne Koller will share progress across our AI-enabled discovery engine & programs advancing toward the clinic, w/ additional participation from our leadership team throughout the week.
www.insitro.com/news/insitro...
www.insitro.com/news/insitro...
New research in Nature Communications validates insitro’s POSH platform for mapping gene function using pooled CRISPR & self-supervised ML.
By preserving rich cellular morphology, POSH reveals biology conventional approaches miss.
🔗 www.nature.com/articles/s41...
By preserving rich cellular morphology, POSH reveals biology conventional approaches miss.
🔗 www.nature.com/articles/s41...
December 16, 2025 at 9:38 PM
New research in Nature Communications validates insitro’s POSH platform for mapping gene function using pooled CRISPR & self-supervised ML.
By preserving rich cellular morphology, POSH reveals biology conventional approaches miss.
🔗 www.nature.com/articles/s41...
By preserving rich cellular morphology, POSH reveals biology conventional approaches miss.
🔗 www.nature.com/articles/s41...
Samuel Sances will be at Intl. Symposium on ALS/MND Sunday to share work from collab. w/ @bristolmyerssquibb.bsky.social. #ML on 200+ patient-derived motor neuron lines, ID'd genes that rescue cellular function, reverse TDP-43 pathology & restore STMN2. symposium.mndassociation.org
#DrugDiscovery
#DrugDiscovery
December 5, 2025 at 5:51 AM
Samuel Sances will be at Intl. Symposium on ALS/MND Sunday to share work from collab. w/ @bristolmyerssquibb.bsky.social. #ML on 200+ patient-derived motor neuron lines, ID'd genes that rescue cellular function, reverse TDP-43 pathology & restore STMN2. symposium.mndassociation.org
#DrugDiscovery
#DrugDiscovery
insitro is proud to welcome Stephen Hitchcock (ex-Takeda CSO) and Vijay Pande (VZVC co-founder, formerly on our Board) as scientific advisors, focused on translating AI-predicted targets into clinical drug candidates through our ChemML platform. www.insitro.com/news/insitro...
December 3, 2025 at 3:43 PM
insitro is proud to welcome Stephen Hitchcock (ex-Takeda CSO) and Vijay Pande (VZVC co-founder, formerly on our Board) as scientific advisors, focused on translating AI-predicted targets into clinical drug candidates through our ChemML platform. www.insitro.com/news/insitro...
From genetic correlation to validated mechanism. Our #MASLD program (CTRO-1013) targeting IRS1 was named a Poster of Distinction at #AASLD2025. We used AI on multimodal data from 263K people to find the target, now validated & advancing to IND-enabling studies. www.insitro.com/news/reveali...
Revealing MASLD's Genetic Architecture: Machine Learning, Discovery, and the Path to IRS1 - insitro
Last week, insitro’s work on IRS1 was recognized as a Poster of Distinction at The Liver Meeting 2025. But the real story isn’t about recognition. It’s about learning to see...
www.insitro.com
November 20, 2025 at 5:35 PM
From genetic correlation to validated mechanism. Our #MASLD program (CTRO-1013) targeting IRS1 was named a Poster of Distinction at #AASLD2025. We used AI on multimodal data from 263K people to find the target, now validated & advancing to IND-enabling studies. www.insitro.com/news/reveali...
Genomic data offers correlation in abundance. Causation requires experimental proof at every step. Join insitro at #AASLD2025. On Monday, 1pm, Poster 4013: learn how platform integration of AI, patient-derived biology & staged validation narrow the gap for MASLD therapeutics.
November 8, 2025 at 12:36 AM
Genomic data offers correlation in abundance. Causation requires experimental proof at every step. Join insitro at #AASLD2025. On Monday, 1pm, Poster 4013: learn how platform integration of AI, patient-derived biology & staged validation narrow the gap for MASLD therapeutics.
We extended our collaboration w/ @bristolmyerssquibb.bsky.social to advance our #ALS target into AI-enabled #drugdiscovery. The next phase is w/ our ChemML™ platform, turning discoveries➡️medicines w/ AI-driven modeling, medicinal chemistry, & structural biology. www.insitro.com/news/insitro...
October 14, 2025 at 8:37 PM
We extended our collaboration w/ @bristolmyerssquibb.bsky.social to advance our #ALS target into AI-enabled #drugdiscovery. The next phase is w/ our ChemML™ platform, turning discoveries➡️medicines w/ AI-driven modeling, medicinal chemistry, & structural biology. www.insitro.com/news/insitro...
We’re @ #ASHG to share our work that uses high-content phenotypic data, genetics & AI/ML to unblock new biology.
@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD
@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk
@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD
@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk
October 14, 2025 at 6:33 PM
We’re @ #ASHG to share our work that uses high-content phenotypic data, genetics & AI/ML to unblock new biology.
@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD
@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk
@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD
@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk
We’re excited to announce a new collaboration with @elilillyandcompany.bsky.social to build next-gen #machinelearning models for small molecule design. www.insitro.com/news/insitro...
September 9, 2025 at 11:20 AM
We’re excited to announce a new collaboration with @elilillyandcompany.bsky.social to build next-gen #machinelearning models for small molecule design. www.insitro.com/news/insitro...
Gabriel blends biology & ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read his Meet the insitrocyte below. arxiv.org/abs/2410.08938
September 3, 2025 at 10:29 PM
Gabriel blends biology & ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read his Meet the insitrocyte below. arxiv.org/abs/2410.08938
7️⃣ years of using AI differently. That means looking where others don’t. . . or can’t.
August 11, 2025 at 6:40 PM
7️⃣ years of using AI differently. That means looking where others don’t. . . or can’t.
@keystonesymposia.bsky.social’s joint conference is coming up! insitro’s Director Max Salick will present at “The Digital Era in Neurodegeneration & Neuroinflammation” to share recent research & technological advances on our POSH platform. Learn more: www.keystonesymposia.org/conferences/...
June 4, 2025 at 7:32 PM
@keystonesymposia.bsky.social’s joint conference is coming up! insitro’s Director Max Salick will present at “The Digital Era in Neurodegeneration & Neuroinflammation” to share recent research & technological advances on our POSH platform. Learn more: www.keystonesymposia.org/conferences/...
Today insitro announces an exciting new collaboration with insighteyehub.bsky.social at Moorfields Eye Hospital, London, through the development of a novel #AI foundation model to identify and to support #drugdiscovery. Learn more: www.businesswire.com/news/home/20...
March 18, 2025 at 10:06 AM
Today insitro announces an exciting new collaboration with insighteyehub.bsky.social at Moorfields Eye Hospital, London, through the development of a novel #AI foundation model to identify and to support #drugdiscovery. Learn more: www.businesswire.com/news/home/20...
Join insitro CEO & founder Daphne Koller at WIRED Health in London Tuesday, March 18 as she takes the keynote stage! 📣 Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI & data at scale.
March 14, 2025 at 1:41 PM
Join insitro CEO & founder Daphne Koller at WIRED Health in London Tuesday, March 18 as she takes the keynote stage! 📣 Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI & data at scale.
Thanks to the SFBT for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...
February 18, 2025 at 3:12 PM
Thanks to the SFBT for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...
Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work.
Visit www.insitro.com/people/.
Visit www.insitro.com/people/.
February 12, 2025 at 4:17 PM
Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work.
Visit www.insitro.com/people/.
Visit www.insitro.com/people/.
As our debut Bluesky post, we’re excited to share our new paper (first author Zachary McCaw) in HGG Advances on scrutinizing the practice of using a ratio trait (numerator / denominator) for GWAS. www.cell.com/hgg-advances...
Excited to share a new paper from @insitro.bsky.social (first author @zmccaw.bsky.social ) in @hggadvances.bsky.social vances.bsky.social on scrutinizing the practice of using a ratio trait (numerator / denominator) for GWAS.
www.cell.com/hgg-advances...
www.cell.com/hgg-advances...
Pitfalls in performing genome-wide association studies on ratio traits
Any variant associated with either numerator or denominator will associate with the
ratio in GWAS of sufficient size. Associations with ratio traits are thus not specific
to the ratio. Instead, we rec...
www.cell.com
February 11, 2025 at 2:41 PM
As our debut Bluesky post, we’re excited to share our new paper (first author Zachary McCaw) in HGG Advances on scrutinizing the practice of using a ratio trait (numerator / denominator) for GWAS. www.cell.com/hgg-advances...